Glomerular Diseases: Registries and Clinical Trials
نویسندگان
چکیده
منابع مشابه
Glomerular Diseases: Registries and Clinical Trials.
Nephrology has conducted few high-quality clinical trials, and the trials that have been conducted have not resulted in the approval of new treatments for primary or inflammatory glomerular diseases. There are overarching process issues that affect the conduct of all clinical trials, but there are also some specialty-specific issues. Within nephrology, primary glomerular diseases are rare, maki...
متن کاملHow to Overcome Scientific Standstill for Very Rare Diseases: Clinical Trials or Clinical Registries?
The ambiguous biology of nodular lymphocyte predominant Hodgkin Lymphoma (NLPHL) – consequences for treatment ▼ NLPHL accounts for about 5 % of all patients with Hodgkin lymphoma (HL) [10], the remaining cases are classified as classical HL (cHL) with nodular sclerosis, mixed cellularity, lymphocyte rich and lymphocyte depleted type as subtypes. Subtyping in cHL has not yet been used for treatm...
متن کاملClinical aspects of glomerular diseases.
Recent advance of modern medicine in the field of renal diseases is remarkable. The favorable treatment result for experimental nephritis, and progress of cellular and humoral immunological studies as well as prevalence of renal biopsy have contributed to elucidate the pathogenic mechanism of glomerular nephritis. Renal biopsy plays an important role to combine clinical findings and morphologic...
متن کاملClinical Trials: the Effects of Registries and Results Databases∗
We analyze the incentives of pharmaceutical firms to generate scientific knowledge through clinical trials and how these incentives are affected through different regulatory environments. We propose a formal model of a pharmaceutical firm’s investment in clinical trials. Our model can explain why voluntary trial registries could not solve the problem of selective reporting of trial results. We ...
متن کاملClinical trials and registries in cardiovascular disease: competitive or complementary?
Mortality from cardiovascular disease continues to decrease in developed countries, due to a combination of factors including changes in socioeconomic status, reduction in risk factors, application of results from clinical trials defining effective treatments, and the ability and infrastructure to translate these findings into clinical practice. We are fortunate to have new therapies that have ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Journal of the American Society of Nephrology
سال: 2016
ISSN: 1555-9041,1555-905X
DOI: 10.2215/cjn.00540116